Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

Moderna and BioNTech have climbed in recent weeks as the resurgent Delta variant has captured headlines.

Moderna and BioNTech stocks are surging amid reports of FDA vaccine-approval progress

Illumina

Johnson & Johnson

Novartis

Regeneron Pharmaceuticals

Zoetis

Let us take a look at what is in store for some of the drug/biotech stocks, which are scheduled to report on Aug 5.

Drug/Biotech Stocks Q2 Earnings Due on Aug 5: REGN, MRNA, ZTS, ILMN

Moderna (MRNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Moderna (MRNA) This Earnings Season?

Hecla Mining

ViacomCBS

Earnings reports released Tuesday morning were again overwhelmingly positive, with the vast majority of companies reporting profits that beat consensus estimates.

Earnings Previews: Hecla Mining, Moderna, ViacomCBS

Moderna stock rallied by more than 12% since our last update on July 19 and remains up by almost 50% over the last month. The gains are driven largely by the inclusion of the stock into the S&P 500 index from July 21, which, in turn, drove demand from index funds and likely from managed funds that.

What's New With Moderna Stock?

The FDA granted Fast Track designation Moderna Inc's (NASDAQ: MRNA) mRNA-1345, its investigational single-dose mRNA vaccine against the respiratory syncytial virus (RSV) in adults older than 60 years of age. The respiratory syncytial virus is a common respiratory virus that generally causes cold-like symptoms.

Moderna RSV-Targeted mRNA Vaccine Candidate Gets Fast Track Tag In US

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna receives FDA Fast Track designation for Respiratory Syncytial Virus (RSV) vaccine (mRNA-1345).

Moderna Receives FDA Fast Track Designation for Respiratory Syncytial Virus (RSV) Vaccine (mRNA-1345)

Pfizer

These elements may represent billions of dollars in the months and years to come.

3 Reasons Why Pfizer's and Moderna's Vaccine Revenue Growth Is Just Getting Started

AstraZeneca

It'll push the winners further ahead of the laggards.

How the Delta Variant Could Change the World of Coronavirus Vaccine Stocks

Moderna Inc (NASDAQ: MRNA) has dosed the first patient in the Phase 1 study of mRNA-6231, its mRNA-encoded IL-2 modified to expand regulatory T cells.  mRNA-6231 is Moderna's first autoimmune candidate to enter the clinic.

Moderna Takes Its First Autoimmune Therapeutic Candidate To Human Trial

Autolus Therapeutics plc (NASDAQ: AUTL) has granted Moderna Inc (NASDAQ: MRNA) an exclusive license to develop and commercialize mRNA therapeutics incorporating Autolus' proprietary binders for up to four immuno-oncology targets. Autolus would be eligible to receive an upfront payment for each target licensed by Moderna and milestone payments.

Autolus Stock Jumps On Cancer mRNA Therapeutics Agreement With Moderna

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces first participant dosed in Phase 1 study of Its IL-2 mRNA therapeutic.

Moderna Announces First Participant Dosed in Phase 1 Study of Its IL-2 mRNA Therapeutic

Vertex Pharmaceuticals

And they should ease investors' biggest concern.

15 Words From Vertex's CEO That Signal Major Growth Ahead

The reported new contracts come as experts mull booster shots to combat the fast-spreading Delta coronavirus variant.

Pfizer and Moderna hiked their COVID-19 vaccine prices in the EU after AstraZeneca lost popularity there, report says

Arcturus Therapeutics

Inovio Pharmaceuticals

Novavax

Ocugen, Inc.

Vaxart

These players delivered triple- and quadruple-digit gains.

Can Last Year's Biggest Vaccine Stocks Crush the Market Again?

Despite alarm around the spread of the Delta COVID variant, vaccine efficacy remains remarkably high. As a result, Moderna and Pfizer are.

Moderna And Pfizer Raise Vaccine Prices In Europe

Pfizer, Inc. (NYSE: PFE) and Moderna, Inc. (NASDAQ: MRNA), which have already minted billions of dollars from their respective COVID-19 vaccines, remain poised to earn more. What Happened: Pfizer and Moderna have both renegotiated their vaccine supply contract with the European Union, the FT reported Sunday.

Pfizer, Moderna Hike Prices Of Vaccine Shots Supplied To EU: Report

There is market concern about the emergence of the Delta variant of SARS-CoV-2. Delta is dangerous, but it looks containable with existing vaccines; the danger comes from new variants that are appearing.

Delta Variant And The Markets

Amazon

Alphabet

Microsoft

The market has been on edge over the new delta variant. Here are five stocks to help blunt a worst-case scenario.

Worried About the Delta Variant? 5 Stocks to Insulate You From a COVID Market Crash

The two companies behind the gene-based COVID vaccines are a lot different than you might think.

Better Biotech Stock: Moderna vs. BioNTech

Catalyst Pharmaceuticals

They might not hit the moon, but there's a much smaller chance they'll bite the dust.

3 Top Robinhood Stocks to Buy in August Instead of Dogecoin

Will Moderna's Tenure on the S&P 500 Index Be Short-Lived?

EPR Properties

Green Brick Partners

IMAX

Lemonade

Looking to make the most of your investing dollars this month? Here are five top stock ideas from Motley Fool experts.

5 Top Stocks For August

Eli Lilly

Starbucks

United Continental Hlds

State Teachers Retirement System of Ohio loaded up on Moderna stock in the second quarter, and lowered investments in Starbucks, United Airlines, and Eli Lilly.

A Huge Pension Bet Big on Moderna Stock. It Sold Starbucks, United, and Eli Lilly.

The firms are already taking the lion's share of earnings from the market, as this week's results will show

News for Moderna Stock (MRNA)